Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
HEДокторантска мрежа2024–2028

MobiliTraIN · Ion Mobility Mass Spectrometry Training Network

„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“

Период
2024-02-01 → 2028-01-31
Финансиране от ЕС
2 716 898 €
Участници
23
Схема
HORIZON-TMA-MSCA-DN

Линиите свързват координатора с партньорите.

Накратко на български

Йонната мобилност и масспектрометрията се използват за точно измерване на молекули, например за откриване на замърсители във водата и храната. Стандартизирането на тези методи помага за по-добро разбиране на развитието на болести и подпомага персонализираната медицина.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Ion Mobility Mass Spectrometry Training Network

Today, ion mobility–high-resolution mass spectrometry (IM-HRMS) is a state-of-the-art analytical platform that can measure and quantify molecules that are central to experimental sciences across disciplines. However, it still faces barriers to express its full potential across sectors. MobiliTraIN aims to unlock the vast application opportunities of IM-HRMS and the specificity this technology offers for routine analytical environments. The overarching objective of MobiliTraIN is to harmonise and standardise IM-HRMS workflows, ensuring the delivery of reliable, high-quality molecular data across health, environmental, and industrial sectors. This pathway to impact begins with generating new fundamental knowledge regarding ion structure, conformation, and the influence of measurement parameters through a combination of experimental and theoretical approaches. In large-scale biomedical studies, where extremely high throughput is needed for routine sample sizes > 1000, IM-HRMS will be advanced to deliver reliable datasets to understand disease onset and progression, supporting personalised medicine. The development of harmonised IM-HRMS non-targeted screening protocols for food, water, and human samples will address the need for rapid and accurate identification of emerging contaminants, which is critical for public health challenges. Finally, by ensuring that IM-HRMS data collection is standardised and easy to implement, MobiliTraIN will secure the long-term value and interoperability of experimental datasets from all major IM-HRMS instrument types.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Ion mobility-high resolution mass spectrometry (IM-HRMS) is the next-generation analytical platform in research and industry. Unlocking its full potential across applications as varied as biotherapeutics, environment and food safety requires not only pushing back the frontiers of instrumentation, fundamental understanding and applications – but harmonisation is essential. To achieve this, current shortcomings in data collection, analysis and reporting across instrument types, laboratories and research areas need to be scrutinised and overcome. The MobiliTraIN Doctoral Network will form 13 Doctoral Candidates (DCs) who will bring a new fundamental understanding of IM-HRMS, provide reference materials and guidelines for standardisation, develop state-of-the-art methods for the application of IM-HRMS in biopharmaceutical development, biological ‘omics studies, and nontarget screening of contaminants, and lay the foundations for IM-HRMS adoption in industry. Through an interdisciplinary research programme, including an open science approach and training in technical, business and transferable skills, the MobiliTraIN DCs will become leading experts in ion mobility with a unique skill set to successfully advance their careers while supporting Europe’s innovation capacity. Building on existing collaborations and research excellence covering the entire innovation chain of IM-HRMS development and application, MobiliTraIN unites 10 academic institutions, 3 leading instrumentation companies, 1 regulatory agency, 1 pharma industry leader and 5 SMEs from 8 countries. With complementary expertise, know-how and mentoring experience, our consortium is ideally suited to unveil the potential of IM-HRMS as a key technology for safer therapeutics, better understanding of complex disease progression and improved monitoring of food, water and public health safety.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз